AD

Buchanan Adds Former ITC Commissioner to International Trade and National Security Practice Group

Retrieved on: 
Thursday, October 19, 2023
Knowledge, Senate, Policy, AD, Dan Sullivan (U.S. senator), Buchanan Ingersoll & Rooney, Legislation, ITC, United States International Trade Commission, Lawyer, Multimedia, CVD, Negotiation, International trade, United

WASHINGTON, Oct. 19, 2023 /PRNewswire/ -- Buchanan Ingersoll & Rooney's International Trade and National Security group, one of the premier practices in the nation, is pleased to announce its latest addition of former U.S. International Trade Commissioner Randolph Stayin.

Key Points: 
  • WASHINGTON, Oct. 19, 2023 /PRNewswire/ -- Buchanan Ingersoll & Rooney's International Trade and National Security group, one of the premier practices in the nation, is pleased to announce its latest addition of former U.S. International Trade Commissioner Randolph Stayin.
  • "We are thrilled to welcome Commissioner Stayin to the firm," said Dan Pickard, shareholder and Chair of the International Trade and National Security Practice.
  • "The scope of his career is beyond impressive, and he has helped shaped the practice of international trade law.
  • "I wanted to join Buchanan because the international trade and national security practice group is a leader in doing important and innovative work for domestic industries that have been injured by unfairly priced imports," said Stayin.

Prediction of Amyloid PET Positivity from Blood-Based Biomarkers, Proteomics, and Clinical Data Discovered through Aitia's Digital Twins to be Presented at CTAD 2023

Retrieved on: 
Thursday, October 19, 2023
AD, Biomarker, Digital twin, Clinical trial, PET, GAP, Disease, Causal AI, Failure, Medical imaging, Alzheimer's disease, Causality (physics)

Aitia's Digital Twins are computational representations of disease that capture genetic and molecular interactions that causally drive clinical and physiological outcomes.

Key Points: 
  • Aitia's Digital Twins are computational representations of disease that capture genetic and molecular interactions that causally drive clinical and physiological outcomes.
  • Specifically, Aitia Gemini Digital Twins have yielded new levels of predictive accuracy of PET positivity across different ethnoracial groups as well as various disease stages.
  • These models may result in a cost-effective and convenient approach to address the high screen failure rate in clinical trial recruitment that currently plagues Alzheimer's clinical trials.
  • This method aims to be accessible to a broader at-risk population while also examining the role of various data sources in predicting PET positivity.

oToBrite Launches a Comprehensive ADAS Product Portfolio for Heavy Commercial Vehicles to Help Road Safety Toward Vision Zero

Retrieved on: 
Thursday, October 19, 2023
DMS, AD, ADAS, Pedestrian, Smoking, GSR, Accident, Safety, Deep learning, UN, MOIS, Build automation, Driver monitoring system, Fatigue, Mobile phone, VRU

Given that heavy commercial vehicles are more likely to be involved in fatal collisions for vulnerable road users (VRU), the latest European Union General Safety Regulations (GSR) have imposed strict standards on heavy commercial vehicles, including BSIS, MOIS, DMS, and other regulations.

Key Points: 
  • Given that heavy commercial vehicles are more likely to be involved in fatal collisions for vulnerable road users (VRU), the latest European Union General Safety Regulations (GSR) have imposed strict standards on heavy commercial vehicles, including BSIS, MOIS, DMS, and other regulations.
  • Japan has also adopted the same regulation for heavy commercial vehicles staring from BSIS UN R151.
  • The whole idea is to make road safety toward vision zero, and oToBrite endeavors to make it come true.
  • In AUTOMOTIVE WORLD Nagoya - October 25-27, 2023, oToBrite will showcase the comprehensive ADAS product at booth 13-19.

oToBrite Launches a Comprehensive ADAS Product Portfolio for Heavy Commercial Vehicles to Help Road Safety Toward Vision Zero

Retrieved on: 
Thursday, October 19, 2023
DMS, AD, ADAS, Pedestrian, Smoking, GSR, Accident, Safety, Deep learning, UN, MOIS, Build automation, Driver monitoring system, Fatigue, Mobile phone, VRU

Given that heavy commercial vehicles are more likely to be involved in fatal collisions for vulnerable road users (VRU), the latest European Union General Safety Regulations (GSR) have imposed strict standards on heavy commercial vehicles, including BSIS, MOIS, DMS, and other regulations.

Key Points: 
  • Given that heavy commercial vehicles are more likely to be involved in fatal collisions for vulnerable road users (VRU), the latest European Union General Safety Regulations (GSR) have imposed strict standards on heavy commercial vehicles, including BSIS, MOIS, DMS, and other regulations.
  • Japan has also adopted the same regulation for heavy commercial vehicles staring from BSIS UN R151.
  • The whole idea is to make road safety toward vision zero, and oToBrite endeavors to make it come true.
  • In AUTOMOTIVE WORLD Nagoya - October 25-27, 2023, oToBrite will showcase the comprehensive ADAS product at booth 13-19.

NKGen Biotech Presents Interim Phase I Trial Data at the XXVI World Congress of Neurology (WCN) Annual Meeting 2023

Retrieved on: 
Tuesday, October 17, 2023
Annual general meeting, Congress, Plasma, Cell, Therapy, Safety, PET, Montreal Cognitive Assessment, ADAS, Patient, ADAS-Cog, MMSE, CSF, Expansion, Poster, Traffic barrier, MRI, AD, Mini–Mental State Examination, NK, Neuroinflammation, WCN, XXVI, Pharmaceutical industry, Medical imaging, QC, Neurology

Severity of AD was based on the baseline Clinical Dementia Rating-Sum of Boxes, or CDR-SB score.

Key Points: 
  • Severity of AD was based on the baseline Clinical Dementia Rating-Sum of Boxes, or CDR-SB score.
  • “The results from our Alzheimer’s trial demonstrate that SNK01 has the potential to cross the blood-brain barrier as evidenced by the CSF biomarker data,” said Paul Y.
  • The pressing need for effective Alzheimer’s treatments cannot be overstated, and we are committed to addressing this healthcare challenge.
  • Based on the CSF biomarker data, intravenous SNK01 appears to cross the blood brain barrier to improve CSF AB42/40 and reduce pTau181 levels.

Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Event with Key Opinion Leaders

Retrieved on: 
Tuesday, October 17, 2023
Identification, UMC, Cognition, Deficit spending, Research, Caregiver, Toxicity, Data, Cell therapy, Safety, Cogstate Brief Battery, Memory, Amsterdam, EEG, DSMB, Data monitoring committee, Fraunhofer Society, MCI, Immunology, QPCT, CBB, Pathology, AD, NTB, Patient, Euronext Amsterdam, Medical imaging, Pharmaceutical industry, Medical device, Amyloid beta

AD is a disorder of cognition, not just memory and MCI and early AD are characterized by a variety of cognitive deficits.

Key Points: 
  • AD is a disorder of cognition, not just memory and MCI and early AD are characterized by a variety of cognitive deficits.
  • It has the advantage of investigating a broad range of cognitive domains acknowledged to be clinically meaningful measures of function.
  • reliability and validity, support its use as an outcome measure in treatment evaluation studies and for use in clinical practice.
  • Based on the results in the SAPHIR study in early AD patients, theta power has been selected as a key secondary endpoint in the VIVIAD study.

AC Immune Announces Upcoming Presentations at the 16th CTAD Conference

Retrieved on: 
Tuesday, October 17, 2023
AD, Medicine, Conference, Pharmaceutical industry

Lausanne, Switzerland, October 17, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced upcoming presentations highlighting its precision medicine pipeline at the 16th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, taking place in Boston, USA, on October 24-27, 2023.

Key Points: 
  • Lausanne, Switzerland, October 17, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced upcoming presentations highlighting its precision medicine pipeline at the 16th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, taking place in Boston, USA, on October 24-27, 2023.
  • ACI-35.030 anti-phospho-Tau active immunotherapy for the treatment of early Alzheimer’s Disease (AD): Update from the Phase 1b/2a study data and perspectives.

Semperis Appoints Former Australian Prime Minister Malcolm Turnbull to Its Strategic Advisory Board

Retrieved on: 
Tuesday, October 17, 2023
Software, Technology, Security, Microsoft, ANZ, BP, Organization, Atrium Health, CIA, OzEmail, Goldman Sachs, Active Directory, Entra, Growth, National Cyber Security Centre (Ireland), Gartner, Walmart, Azure AD Connect, Okta, AD, News, Politics, Ciso, National Cyber Security Division, Risk management, Hydrophis semperi

Semperis , a pioneer in identity-driven cyber resilience, today announced the appointment of former Australian Prime Minister Malcolm Turnbull to its strategic advisory board.

Key Points: 
  • Semperis , a pioneer in identity-driven cyber resilience, today announced the appointment of former Australian Prime Minister Malcolm Turnbull to its strategic advisory board.
  • “In the world of cybersecurity, identity is the new perimeter and business leaders are taking notice,” said Turnbull.
  • As Australia’s 29th Prime Minister, Turnbull launched the country’s first national cybersecurity strategy.
  • To learn more about Semperis, its advisory board and solutions, visit semperis.com.

Alzheon to Present Biomarker, Brain Preservation, and Clinical Results from Pivotal Program of Oral ALZ-801/Valiltramiprosate at 16th Annual Clinical Trials in Alzheimer’s Disease Conference

Retrieved on: 
Tuesday, October 17, 2023
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Cerebrospinal fluid, Doctor of Philosophy, Plasma, Amyloid, Oral, Brain, MD, Neurotoxicity, Risk, Clinical trial, Cerebral amyloid angiopathy, Safety, APOE4, Biomarker, Ageing, Cerebral edema, CSF, NDA, Organic chemistry, Genotype, Czech Institute For International Meetings, AD, Patient, Pharmaceutical industry, Medical imaging, Alzheon, Early

We are pleased with the growing body of evidence that supports ALZ-801’s potential as the first oral anti-amyloid disease modifying therapy for Alzheimer’s disease,” said Martin Tolar, MD, PhD, Founder, President, and CEO of Alzheon.

Key Points: 
  • We are pleased with the growing body of evidence that supports ALZ-801’s potential as the first oral anti-amyloid disease modifying therapy for Alzheimer’s disease,” said Martin Tolar, MD, PhD, Founder, President, and CEO of Alzheon.
  • “Our efficacy data combined with a favorable safety profile with no events of vasogenic edema underscore the differentiated clinical profile of ALZ-801 tablet.
  • In mechanism of action studies, ALZ-801 fully blocked the formation of neurotoxic soluble beta amyloid (Aβ) oligomers at the Phase 3 clinical dose.
  • In addition, Alzheon is collaborating with the Czech Institute of Organic Chemistry & Biochemistry (IOCB) to develop an assay to measure the neurotoxic amyloid oligomers in CSF.

Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer’s Study

Retrieved on: 
Thursday, October 12, 2023
NYSE, Safety, Update, DSMB, FDA, Gian Maria Annovi, Clutch (eggs), AD, PD, Patient, Cognition, Pharmaceutical industry

The Company has received the results of the pre-planned interim analysis conducted by an independent data analytics provider.

Key Points: 
  • The Company has received the results of the pre-planned interim analysis conducted by an independent data analytics provider.
  • The interim analysis was based on 107 patients at 6 weeks from all cohorts collectively and showed that the AD trial should continue as planned with the same trial size to maintain the statistical power for both co-primary endpoints.
  • A separate safety interim analysis is in process and we expect that interim analysis to be released in two weeks.
  • Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis, commented: “Although we remain blinded to the data, results from this interim analysis supports our original statistical powering for enrolling 320 patients into the Phase 2/3 Alzheimer’s study.